Developer docs
API playgroundTry for free, no card

Search company profiles

D&D Pharmatech

Full company profile

uuid0000s27

Namestring
D&D Pharmatech
Legal namestring
(주)디앤디파마텍
Company typeenum
Public
Founded yearint
2014
Descriptiontext

D&D Pharmatech is a clinical-stage South Korean biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic, neurodegenerative, and fibrotic diseases. Its lead asset, DD01 (Zabopegdutide), is a GLP-1/glucagon dual-receptor agonist that demonstrated statistically significant Phase 2 48-week biopsy results in MASH at EASL 2026, with 81.8% of treated patients achieving ≥1-stage fibrosis improvement versus 18.8% on placebo. The pipeline also includes NLY01 (Pegsebrenatide), a GLP-1 receptor agonist in Phase 2 for progressive multiple sclerosis with Parkinson's and Alzheimer's in development, and TLY012, a first-in-class fibrosis treatment with FDA IND approval.

The company's technical differentiation rests on two proprietary platforms: ORALINK, an oral peptide formulation technology that enables tablet-form delivery of peptide drugs traditionally administered by injection, and Valted Seq (HiF-Seq™), an AI-driven big data platform for degenerative brain disease target discovery. D&D Pharmatech operates a US-dedicated clinical infrastructure through wholly-owned subsidiary Neuraly Inc., and holds a 15% stake in G-Alpha Therapeutics, a US affiliate developing alpha radiopharmaceutical cancer therapies using Astatine-211. Co-founders include Johns Hopkins researchers Ted M. Dawson, Valina L. Dawson, and Martin G. Pomper (inventor of the blockbuster PSMA PET imaging agent PYLARIFY).

As a pre-revenue clinical-stage company, D&D Pharmatech does not yet commercialize products and generates no product revenue. Its business model is structured around advancing its pipeline through clinical milestones to enable global out-licensing transactions with major pharmaceutical partners, supplemented by capital markets activity (KOSDAQ IPO in April 2024 and a 226.5 billion KRW convertible bond in April 2026) and strategic AI partnerships (LG AI Research). Future monetization is expected through upfront and milestone payments from licensing deals, with the company actively pursuing global technology out-licensing negotiations for DD01 following positive Phase 2 results.

Short descriptiontext

D&D Pharmatech is a South Korean clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for MASH, obesity, neurodegenerative diseases, and fibrosis, leveraging proprietary ORALINK oral peptide and AI-driven Valted Seq platforms, and monetizing through pipeline out-licensing to global pharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
GLP-1 therapeutics, metabolic disease drugs, MASH treatment, peptide drug development, oral peptide formulations
Industry4 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

D&D Pharmatech is a clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic diseases (MASH, obesity), neurodegenerative diseases (Parkinson's disease, multiple sclerosis), and fibrosis. Its pipeline includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist in Phase 2 for MASH; NLY01 (Pegsebrenatide) for neurodegenerative diseases; and TLY012, a first-in-class fibrosis treatment. The company leverages its proprietary ORALINK oral peptide formulation platform and AI-driven drug discovery partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 81.8% of zabopegdutide-treated patients achieved >=1-stage fibrosis improvement vs 18.8% on placebo (p=0.001) at 48 weeks
+3 more records
Product overview1 text field

D&D Pharmatech is a South Korean biotech company specializing in GLP-1 peptide-based metabolic disease therapeutics. The core product portfolio includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist for MASH and obesity currently in Phase 2 trials available in oral and injectable forms; NLY01 (Pegsebrenatide) for progressive multiple sclerosis and Parkinson's disease in Phase 2; and TLY012, a first-in-class fibrosis treatment entering Phase 1. The company operates proprietary technology platforms including ORALINK for oral peptide delivery and Valted Sequencing (Valted Seq) for AI-driven target discovery in degenerative brain diseases. Through its U.S. subsidiary Neuraly, the company develops neurodegeneration treatments, while G-Alpha Therapeutics focuses on alpha radiopharmaceutical cancer therapies.

Product and service3 records
1DD01 (Zabopegdutide)
CategoryGLP-1 Metabolic Disease Therapeutic
Description

Dual GLP-1 and glucagon receptor agonist in Phase 2 clinical development for metabolic dysfunction-associated steatohepatitis (MASH), available in both oral and injectable formulations. The dual-receptor mechanism produces rapid liver fat reduction and has demonstrated statistically significant fibrosis improvement (81.8% achieving ≥1-stage fibrosis improvement vs 18.8% placebo) and MASH resolution at 48 weeks.

2NLY01 (Pegsebrenatide)
CategoryGLP-1 Neurodegenerative Disease Therapeutic
Description

GLP-1 receptor agonist in Phase 2 clinical trials for progressive multiple sclerosis, with additional development for Parkinson's disease and Alzheimer's disease. Targets a novel neuroprotective mechanism originally identified at Johns Hopkins University, with the program operated through U.S. subsidiary Neuraly Inc.

3TLY012
CategoryAnti-Fibrosis Therapeutic
Description

First-in-class fibrosis treatment targeting liver fibrosis with FDA IND approval, advancing into U.S. Phase 1/2 clinical development. Funded by the company's 2026 convertible bond issuance alongside the DD01 program.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for MASH and obesity in Phase 2b. Directly comparable mechanism to DD01 and competing for the same dual-agonist MASH positioning.

TypeDirect peer
Description

US clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH in Phase 3 (SYNCHRONY program). Same indication (MASH) with strong histology data, competing for second-line MASH positioning behind Madrigal's Rezdiffra.

TypeDirect peer
Description

US clinical-stage biotech developing integrin-based therapies for fibrosis, including bexotegrast for idiopathic pulmonary fibrosis (Phase 2b/3). Directly comparable to D&D's TLY012 in fibrosis space with similar clinical-stage status and indication focus.

TypeDirect peer
Description

US biotech with first FDA-approved MASH drug Rezdiffra (resmetirom, a thyroid hormone receptor-beta agonist). Sets the benchmark for MASH commercial success and is the incumbent DD01 must displace or follow in clinical positioning.

TypeDirect peer
Description

US clinical-stage biotech developing VK2735 (GLP-1/GIP dual agonist) for obesity and VK2809 for MASH. Highly relevant peer given adjacent incretin mechanism (GLP-1) and overlapping obesity/MASH indications.

TypeDirect peer
Description

US clinical-stage biotech focused on obesity and MASH with TERN-501 (THR-β agonist) and TERN-800 series (GLP-1). Same therapeutic areas as D&D with comparable clinical-stage positioning and partnership-driven strategy.

TypeBroad incumbent
Description

Global GLP-1 leader with Ozempic/Wegovy (semaglutide) for diabetes/obesity and pipeline MASH candidates. Sets the commercial benchmark for GLP-1 success and is the dominant force DD&D must compete against in obesity and potentially MASH.

TypeDirect peer
Description

Denmark-based clinical-stage biotech co-developing survodutide, a GLP-1/glucagon dual agonist for MASH and obesity with Boehringer Ingelheim — the most directly competitive asset to D&D's DD01/Zabopegdutide due to identical mechanism and overlapping indications.

TypeBroad incumbent
Description

Global pharma with Mounjaro/Zepbound (tirzepatide, GLP-1/GIP) dominating obesity/diabetes. Major incumbent setting commercial dynamics and out-licensing benchmarks that any GLP-1 success — including DD01 — must be measured against.

TypeEmerging player
Description

US clinical-stage biotech focused on TGF-beta family therapeutics for hematology and fibrosis (e.g., KER-050, KER-047). Comparable to D&D as a smaller clinical-stage biotech with fibrosis-adjacent pipeline and similar development-stage profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

D&D Pharmatech

Biopharmaceutical Therapeuticsddpharmatech.com

D&D Pharmatech is a South Korean clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for MASH, obesity, neurodegenerative diseases, and fibrosis, leveraging proprietary ORALINK oral peptide and AI-driven Valted Seq platforms, and monetizing through pipeline out-licensing to global pharma partners.

What D&D Pharmatech does

D&D Pharmatech is a clinical-stage South Korean biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic, neurodegenerative, and fibrotic diseases. Its lead asset, DD01 (Zabopegdutide), is a GLP-1/glucagon dual-receptor agonist that demonstrated statistically significant Phase 2 48-week biopsy results in MASH at EASL 2026, with 81.8% of treated patients achieving ≥1-stage fibrosis improvement versus 18.8% on placebo. The pipeline also includes NLY01 (Pegsebrenatide), a GLP-1 receptor agonist in Phase 2 for progressive multiple sclerosis with Parkinson's and Alzheimer's in development, and TLY012, a first-in-class fibrosis treatment with FDA IND approval.

The company's technical differentiation rests on two proprietary platforms: ORALINK, an oral peptide formulation technology that enables tablet-form delivery of peptide drugs traditionally administered by injection, and Valted Seq (HiF-Seq™), an AI-driven big data platform for degenerative brain disease target discovery. D&D Pharmatech operates a US-dedicated clinical infrastructure through wholly-owned subsidiary Neuraly Inc., and holds a 15% stake in G-Alpha Therapeutics, a US affiliate developing alpha radiopharmaceutical cancer therapies using Astatine-211. Co-founders include Johns Hopkins researchers Ted M. Dawson, Valina L. Dawson, and Martin G. Pomper (inventor of the blockbuster PSMA PET imaging agent PYLARIFY).

As a pre-revenue clinical-stage company, D&D Pharmatech does not yet commercialize products and generates no product revenue. Its business model is structured around advancing its pipeline through clinical milestones to enable global out-licensing transactions with major pharmaceutical partners, supplemented by capital markets activity (KOSDAQ IPO in April 2024 and a 226.5 billion KRW convertible bond in April 2026) and strategic AI partnerships (LG AI Research). Future monetization is expected through upfront and milestone payments from licensing deals, with the company actively pursuing global technology out-licensing negotiations for DD01 following positive Phase 2 results.

D&D Pharmatech firmographics

Firmographics
Name
D&D Pharmatech
Legal name
(주)디앤디파마텍
Website
https://ddpharmatech.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
D&D Pharmatech is a South Korean clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for MASH, obesity, neurodegenerative diseases, and fibrosis, leveraging proprietary ORALINK oral peptide and AI-driven Valted Seq platforms, and monetizing through pipeline out-licensing to global pharma partners.
Ownership category
akta.pro rank

D&D Pharmatech industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • GLP-1 therapeutics
  • Metabolic disease drugs
  • MASH treatment
  • Peptide drug development
  • Oral peptide formulations

Where D&D Pharmatech is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Markets served

D&D Pharmatech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Distribution channels1 record

Marketing channels3 records

D&D Pharmatech product offering

Product offering

Core offering

D&D Pharmatech is a clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic diseases (MASH, obesity), neurodegenerative diseases (Parkinson's disease, multiple sclerosis), and fibrosis. Its pipeline includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist in Phase 2 for MASH; NLY01 (Pegsebrenatide) for neurodegenerative diseases; and TLY012, a first-in-class fibrosis treatment. The company leverages its proprietary ORALINK oral peptide formulation platform and AI-driven drug discovery partnerships.

Product overview

D&D Pharmatech is a South Korean biotech company specializing in GLP-1 peptide-based metabolic disease therapeutics. The core product portfolio includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist for MASH and obesity currently in Phase 2 trials available in oral and injectable forms; NLY01 (Pegsebrenatide) for progressive multiple sclerosis and Parkinson's disease in Phase 2; and TLY012, a first-in-class fibrosis treatment entering Phase 1. The company operates proprietary technology platforms including ORALINK for oral peptide delivery and Valted Sequencing (Valted Seq) for AI-driven target discovery in degenerative brain diseases. Through its U.S. subsidiary Neuraly, the company develops neurodegeneration treatments, while G-Alpha Therapeutics focuses on alpha radiopharmaceutical cancer therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • DD01 (Zabopegdutide) Dual GLP-1 and glucagon receptor agonist in Phase 2 clinical development for metabolic dysfunction-associated steatohepatitis (MASH), available in both oral and injectable formulations. The dual-receptor mechanism produces rapid liver fat reduction and has demonstrated statistically significant fibrosis improvement (81.8% achieving ≥1-stage fibrosis improvement vs 18.8% placebo) and MASH resolution at 48 weeks.
  • NLY01 (Pegsebrenatide) GLP-1 receptor agonist in Phase 2 clinical trials for progressive multiple sclerosis, with additional development for Parkinson's disease and Alzheimer's disease. Targets a novel neuroprotective mechanism originally identified at Johns Hopkins University, with the program operated through U.S. subsidiary Neuraly Inc.
  • TLY012 First-in-class fibrosis treatment targeting liver fibrosis with FDA IND approval, advancing into U.S. Phase 1/2 clinical development. Funded by the company's 2026 convertible bond issuance alongside the DD01 program.

Quantifiable outcome

  • 81.8% of zabopegdutide-treated patients achieved >=1-stage fibrosis improvement vs 18.8% on placebo (p=0.001) at 48 weeks
  • +3 more outcomes

Companies that use D&D Pharmatech

Customer profile

Segments1 record

Ideal customer profiles1 record

D&D Pharmatech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

D&D Pharmatech partnerships and signals

Strategic signal

Recent moves9 records

Expansion highlights6 records

D&D Pharmatech competitors and assessment

Company assessment

Direct peers

  • Altimmune: US clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for MASH and obesity in Phase 2b. Directly comparable mechanism to DD01 and competing for the same dual-agonist MASH positioning.
  • Akero Therapeutics: US clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH in Phase 3 (SYNCHRONY program). Same indication (MASH) with strong histology data, competing for second-line MASH positioning behind Madrigal's Rezdiffra.
  • Pliant Therapeutics: US clinical-stage biotech developing integrin-based therapies for fibrosis, including bexotegrast for idiopathic pulmonary fibrosis (Phase 2b/3). Directly comparable to D&D's TLY012 in fibrosis space with similar clinical-stage status and indication focus.
  • Madrigal Pharmaceuticals: US biotech with first FDA-approved MASH drug Rezdiffra (resmetirom, a thyroid hormone receptor-beta agonist). Sets the benchmark for MASH commercial success and is the incumbent DD01 must displace or follow in clinical positioning.
  • Viking Therapeutics: US clinical-stage biotech developing VK2735 (GLP-1/GIP dual agonist) for obesity and VK2809 for MASH. Highly relevant peer given adjacent incretin mechanism (GLP-1) and overlapping obesity/MASH indications.
  • Terns Pharmaceuticals: US clinical-stage biotech focused on obesity and MASH with TERN-501 (THR-β agonist) and TERN-800 series (GLP-1). Same therapeutic areas as D&D with comparable clinical-stage positioning and partnership-driven strategy.
  • Zealand Pharma: Denmark-based clinical-stage biotech co-developing survodutide, a GLP-1/glucagon dual agonist for MASH and obesity with Boehringer Ingelheim — the most directly competitive asset to D&D's DD01/Zabopegdutide due to identical mechanism and overlapping indications.

Broad incumbents

  • Novo Nordisk: Global GLP-1 leader with Ozempic/Wegovy (semaglutide) for diabetes/obesity and pipeline MASH candidates. Sets the commercial benchmark for GLP-1 success and is the dominant force DD&D must compete against in obesity and potentially MASH.
  • Eli Lilly: Global pharma with Mounjaro/Zepbound (tirzepatide, GLP-1/GIP) dominating obesity/diabetes. Major incumbent setting commercial dynamics and out-licensing benchmarks that any GLP-1 success — including DD01 — must be measured against.

Emerging players

  • Keros Therapeutics: US clinical-stage biotech focused on TGF-beta family therapeutics for hematology and fibrosis (e.g., KER-050, KER-047). Comparable to D&D as a smaller clinical-stage biotech with fibrosis-adjacent pipeline and similar development-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

D&D Pharmatech social profiles

Digital presence

D&D Pharmatech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

D&D Pharmatech leadership team

Management profile

Number of profiles

Profiles5 records

D&D Pharmatech subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

D&D Pharmatech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

D&D Pharmatech M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about D&D Pharmatech

What does D&D Pharmatech do?

D&D Pharmatech is a clinical-stage biopharmaceutical company developing GLP-1 peptide-based therapeutics for metabolic diseases (MASH, obesity), neurodegenerative diseases (Parkinson's disease, multiple sclerosis), and fibrosis. Its pipeline includes DD01 (Zabopegdutide), a dual GLP-1/glucagon receptor agonist in Phase 2 for MASH; NLY01 (Pegsebrenatide) for neurodegenerative diseases; and TLY012, a first-in-class fibrosis treatment. The company leverages its proprietary ORALINK oral peptide formulation platform and AI-driven drug discovery partnerships.

Is D&D Pharmatech a public or private company?

D&D Pharmatech is a public company. It is classified as public and is currently operating.

When was D&D Pharmatech founded?

D&D Pharmatech was founded in 2014. It employs 11 to 50 people.

Where is D&D Pharmatech based?

D&D Pharmatech is headquartered in Seongnam, South Korea, in the Asia region.

Who are D&D Pharmatech's main competitors?

Direct peers on record are Altimmune, Akero Therapeutics, Pliant Therapeutics, Madrigal Pharmaceuticals, Viking Therapeutics, Terns Pharmaceuticals and Zealand Pharma. Broad incumbents are Novo Nordisk and Eli Lilly. Keros Therapeutics is listed as an emerging player.

Does D&D Pharmatech have an API?

No public API is recorded for D&D Pharmatech.

What industry is D&D Pharmatech in?

D&D Pharmatech's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyD&D Pharmatech lines up liver fibrosis drug for 2027D&D Pharmatech's TLY012, a liver fibrosis drug, is set to begin Phase 1 in the first half of 2027. The company's NLY01 failed its primary endpoint in a Parkinson's Phase 2 trial, but patients under 60 showed benefit, leading to an investigator-initiated Phase 2 trial in multiple sclerosis.Dealroom.coZ-Alpha pulls in $7.48M round as global pharma joins alpha-therapy bet | Dealroom NewsZ-Alpha raised $8.38M in a late-stage venture round led by Korea's d&d pharmatech, with an unnamed global pharma joining. The biotech will use funds to advance astatine-211-based cancer therapies toward clinical trials in 2027. The short half-life of the isotope poses a key manufacturing hurdle.Longevity.TechnologyZabopegdutide shows 63% MASH resolution in Phase 2 trialD&D Pharmatech presented final 48-week Phase 2 liver biopsy data for Zabopegdutide at the AASLD meeting in November 2026. The treated group achieved 62.5% MASH resolution versus 5.3% for placebo, and 50.0% fibrosis improvement versus 15.8%. The company is advancing global licensing-out negotiations.Business & FinancialBIX 2026 Counts Down To Opening With Post-GLP-1 Session On The Next Obesity Treatment MarketBIX 2026, Korea's largest biotech and pharma convention, will open October 28-30 at COEX Seoul with over 300 companies and 90 speakers. A dedicated Post-GLP-1 session will examine next-generation obesity treatments, with speakers from JVC, Innovent, Hanmi, and D&D Pharmatech discussing investment, pricing, and global strategies.NaverDongKoo Bio & Pharma Sees Investment Gains Take Shape as Quriant, D&D Pharmatech AdvanceDongKoo Bio & Pharma-backed companies are advancing commercialization and clinical trials. Quriant signed a global co-commercialization deal with Lonza for an ADC platform, while D&D Pharmatech reported positive MASH results in a Phase 2 study. Novacell Technology is pursuing a Kosdaq listing.PRLogBIX 2026 Counts Down to Opening with Post-GLP-1 Session on the Next Obesity Treatment MarketBIX 2026, Korea's largest biotech and pharma convention, will open Oct. 28–30 at COEX Seoul with over 300 companies and 90 speakers. A featured session on post-GLP-1 obesity treatments will include experts from CBC Group, Innovent Biologics, Hanmi Pharmaceutical, and D&D Pharmatech, discussing market leadership and expansion strategies.Longevity.TechnologyZabopegdutide shows rapid, weight-independent liver benefits in Phase 2D&D Pharmatech announced publication in The Lancet Gastroenterology & Hepatology of 12-week Phase 2 trial results for zabopegdutide (DD01) in 67 patients with MASLD/MASH, showing 75.8% achieved at least 30% liver fat reduction and 48.5% achieved liver fat normalization. The drug demonstrated weight-loss-independent hepatic effects, with patients experiencing 37.4% liver fat reduction and 19.2% liver stiffness reduction even without significant body weight loss, alongside progressive weight loss reaching 6.4% at 24 weeks.BioSpaceD&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASHD&D Pharmatech published 12-week Phase 2 data for zabopegdutide in the Lancet Gastroenterology & Hepatology, showing rapid reductions in liver fat, stiffness, and fibrosis biomarkers. These improvements preceded weight loss and predicted the statistically significant histological benefits seen at 48 weeks. The company plans to advance the program into late-stage clinical development.AijournD&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASHD&D Pharmatech announced publication of 12-week Phase 2 data for zabopegdutide (DD01) in the Lancet Gastroenterology & Hepatology, showing rapid improvements in liver fat, liver stiffness, and fibrosis biomarkers in MASLD/MASH patients. The key finding distinguishes zabopegdutide from conventional incretin therapies by demonstrating significant liver health improvements that occurred before meaningful weight loss, providing evidence of direct hepatic activity beyond weight reduction effects. The company stated it looks forward to advancing the program into late-stage clinical development following the statistically significant histological improvements observed at 48 weeks.Investing.comD&D Pharmatech publishes 12-week zabopegdutide MASH study data By Investing.comD&D Pharmatech announced publication of 12-week results from its Phase 2 study evaluating zabopegdutide in patients with metabolic dysfunction-associated steatohepatitis in the Lancet Gastroenterology & Hepatology. The randomized, double-blind, placebo-controlled trial enrolled 67 overweight or obese patients with MASLD/MASH who received 40 mg of zabopegdutide once weekly, with 75.8% achieving at least 30% reduction in liver fat and 72.7% achieving greater than 50% reduction. The treatment also produced reductions in liver stiffness and fibrosis biomarkers, with patients experiencing 3.8% weight loss at 12 weeks and 6.4% at 24 weeks, and was generally well tolerated.